TROP2 and TIGIT Therapies for Advanced NSCLC: Where Are We Today?

In this Clinical Care Options Oncology podcast, Dr. Alex Spira and Dr. Benjamin Levy discuss recent developments in TROP2 and TIGIT therapies for lung cancer treatment, referencing data from ESMO 2025. They analyze the disappointing results of the TROPI and EVOKE-01 studies, which failed to show overall survival benefits with TROP2 ADCs compared to docetaxel in advanced non-small cell lung cancer. They explore the potential of TROP2 NMR as a predictive biomarker and debate the role of TROP2 ADCs in first-line treatment, questioning whether they can replace Pemetrexid due to toxicity concerns. The doctors also review salvaged data on datopotamab deruxtecan in EGFR-mutated populations and discuss the promise and challenges of TIGIT-targeted therapies, particularly bispecific antibodies like rivagostamig.